Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China
· Delayed Price · Currency is CNY 19.83
+0.63 (3.28%)
Apr 29, 2026, 3:13 PM CST
SHE:300497 Revenue
Jiangxi Fushine Pharmaceutical had revenue of 357.76M CNY in the quarter ending March 31, 2026, with 53.09% growth. This brings the company's revenue in the last twelve months to 1.31B, up 22.21% year-over-year. In the year 2025, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B with 0.61% growth.
Revenue (ttm)
1.31B
Revenue Growth
+22.21%
P/S Ratio
8.16
Revenue / Employee
n/a
Employees
1,774
Market Cap
10.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18B | 7.14M | 0.61% |
| Dec 31, 2024 | 1.18B | -431.82M | -26.83% |
| Dec 31, 2023 | 1.61B | -37.59M | -2.28% |
| Jan 1, 2023 | 1.65B | 217.72M | 15.23% |
| Jan 1, 2022 | 1.43B | -63.41M | -4.25% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HitGen | 525.57M |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.90B |
| Chengdu Easton Biopharmaceuticals | 1.35B |
| Chongqing Genrix Biopharmaceutical | 230.72M |
| Hualan Biological Vaccine | 1.20B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Beijing Hotgen Biotech | 404.88M |
| Liaoning Chengda Biotechnology | 1.39B |